Nexus Finance
ENOV Enovis Corporation | US1940145022

Company Profile

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Latest News

Sector Healthcare
Industry Medical Devices
Website https://www.enovis.com
Audit Risk 6
Board Risk 1
Overall Risk 1
Market Cap 1.56B
Forward P/E 6.63
Trailing Annual Div. Rate 0
Trailing Annual Div. Yield 0.00%
Trailing EPS -19.89
Forward EPS 4.08
Book Value 25.66
Price-to-Book 1.05
Enterprise-to-Revenue 1.29
Enterprise-to-EBITDA 7.89
Short Ratio 6.46
Earnings Date 08/06/2026
Earnings Call Date 08/06/2026
Earnings Average 0.85
Earnings Low 0.8
Earnings High 0.9
Revenue Average 582.45M
Revenue Low 576.00M
Revenue High 590.30M
ende